Bexmarilimab

Bexmarilimab (FP-1305) is a potent humanized anti-CLEVER-1 IgG4 antibody with an IC50 value of 4.51 nM. Bexmarilimab is capable of inducing a phenotypic M2 to M1 immune switch of tumor-associated macrophages. Bexmarilimab can promote antigen presentation and pro-inflammatory cytokine secretion. Bexmarilimab can induce B-cell and T-cell activation. Bexmarilimab can be used in researches of immunology and cancer, such as colorectal carcinoma[1][2].

Product Specifications

CAS Number

[2259301-27-2]

Product Name Alternative

FP-1305

UNSPSC

12352203

Target

Transmembrane Glycoprotein

Type

Inhibitory Antibodies

Related Pathways

Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/bexmarilimab.html

Purity

95.00

Solubility

10 mM in DMSO

Smiles

[Bexmarilimab]

Molecular Weight

(146.22 kDa)

References & Citations

[1]Hollmén M, et al. Nonclinical Characterization of Bexmarilimab, a Clever-1-Targeting Antibody for Supporting Immune Defense Against Cancers. Mol Cancer Ther. 2022 Jul 5;21 (7) :1207-1218.|[2]Elisa M. Vuorinen, et al. Bexmarilimab induces B-cell activation and autoantibody production. Cancer Res 1 April 2023; 83 (7_Supplement) : 2269.